Panel Discussion: Deploying Molecular Glues to Tackle Neurodegeneration’s Toughest Targets

• How can molecular glues be leveraged to target pathogenic protein aggregates and drive the selective clearance of disease-causing proteins across Alzheimer’s, Parkinson’s, and Huntington’s disease?
• What strategies are proving most effective for engineering brain-penetrant molecular glues that improve CNS exposure and target engagement while enhancing the translational potential of neurodegeneration programs?
• How can target engagement be most effectively validated in disease-relevant neuronal models to better understand therapeutic impact and de-risk progression into clinical development?

Speakers:

Rick Ewing

Vice President & Head of Chemistry

Rapafusyn

Evris Gavathiotis

Professor of Biochemistry, Medicine, and Oncology

Albert Einstein College of Medicine

Charlie Hao

Chief Scientific Officer

Degron Therapeutics